Saes L, Eskens F A L M
Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands.
Drugs Today (Barc). 2017 Nov;53(11):609-618. doi: 10.1358/dot.2017.53.11.2724804.
Tivozanib is a tyrosine kinase inhibitor that targets all vascular endothelial growth factor receptors (VEGFRs), causing inhibition of angiogenesis. It has recently been approved by the European Medicines Agency (EMA) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive, following disease progression after one prior treatment with cytokine therapy for advanced RCC. This review will focus on mechanisms of action, early drug development and results of published and ongoing clinical trials of tivozanib.
替沃扎尼是一种酪氨酸激酶抑制剂，可作用于所有血管内皮生长因子受体（VEGFRs），从而抑制血管生成。它最近已获得欧洲药品管理局（EMA）批准，用于一线治疗晚期肾细胞癌（RCC）的成年患者，以及既往接受过一次晚期RCC细胞因子治疗后疾病进展、且未使用过VEGFR和雷帕霉素哺乳动物靶点（mTOR）通路抑制剂的成年患者。本综述将聚焦于替沃扎尼的作用机制、早期药物研发以及已发表和正在进行的临床试验结果。
